Sichuan Biokin Stock Hits Day Low Amid Price Pressure, Drops to CNY 219.09

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a significant decline in its stock performance today, with a drop of 6.83% as it reached an intraday low of CNY 219.09. This downturn is part of a broader trend, as the stock has seen a decrease of 12.2% over the past week and 19.56% over the last month. Year-to-date, the stock has fallen by 32.03%, contrasting sharply with the China Shanghai Composite, which has gained 3.27% during the same period. The company's financial metrics reflect ongoing challenges, with net sales for the first nine months showing a decline of 63.52%, amounting to CNY 2,065.9 million. Additionally, the net profit for the same period was reported at CNY -500.37 million, marking a significant drop of 112.34%. The operating cash flow has also reached a low of CNY -2,331.46 million. Despite a notable 134.87% increase over the past three years, the current performance indicators suggest a challenging environment for Sichuan Biokin Pharmaceutical, as it navigates through a period of negative results and fluctuating market conditions.